A 1982 study of 76 patients conducted by the Dermatological Department of the General Hospital of Valencia, Spain showed a 77.6% good to very good response to a 0.2% zinc pyrithione spray. Three sprays per day were administered. It took an average of 6.2 days to get a therapeutic response. The only side effect noted was an irritation when applied to itchy skin.
It is the ability of C. forskohlii to activate intracellular cAMP that makes it so valuable as a therapeutic component of Asthma End. Forskolin stimulates the enzyme adenylate cyclase to release cAMP. cAMP levels rise which inhibits the release of chemical mediators. This relaxes bronchial smooth muscle and prevents bronchospasm.
In 1995 a double-blind, placebo-controlled study was conducted at the Finochietto Hospital in Buenos Aries, Argentina. In this study patients had to have had psoriasis for a year with symmetrical lesions on both sides of the body. Unmarked bottles were used on the lesions on both right and left sides of the body. The bottle with the 0.2% zinc pyrithione was very effective in reducing the desquamation and erythema of the plaques.
Zinc pyrithione was first discovered in 1936 and patented in 1937 by Hoffman-La Roche. Medicinally, it has been used as a fungicide and bactericide. Zinc pyrithione's therapeutic classification has been as an antibacterial, antifungal, and anti-seborrheic. Zinc pyrithione is part of the active ingredients in "Selsen-Blue" and "Head & Shoulders". It has been extensively used in Europe for the last ten years.
Zinc pyrithione has proven effective against pityrossporum yeasts which can cause acne-like skin disease. It can also be used against athlete's foot, poison ivy and yeast infections.
Zinc pyrithione has worked effectively with patients without dietary or other nutritional supplementation. Patients who are treated with diet and nutrition should do even better.
Psoriasis is biochemically characterized by a decrease in cAMP(cyclic adenosine monophosphate) in relation to cGMP(cyclic guanosine monophosphate). This shift causes a tremendous increase in cell division. Psoriatic cells divided at a rate of 1,000 times the rate of normal cells. This results in the common clinical symptoms of itching and flaking that is so prevalent in psoriasis. It also explains the hallmark plaques and lesions of the disease.
Coleus forskohlii is an Aryvedic herb that increases cAMP. Over 5,000 in-vitro and in-vivo studies from 1981 to 1994 have looked at Coleus' ability to increase cAMP. The principal compound studied is forskolin. Herbal extracts are of the rootstock and standardized to their percentage content of forskolin. Forskolin activates the enzyme adenylate cyclase. This enzyme then increases intra-cellular cAMP. New research shows that forskolin also inhibits a number of membrane transport proteins and channel proteins not related to cAMP production.
It is the ability of C. forskohlii to activate in-tracellular cAMP that makes it so valuable as a therapeutic component of Derma Clear. Rebalancing the ratios between cAMP and cGMP will cause the psoriatic cells to cease their pell-mell reproduction allowing normal cell division to reestablish itself with the appearance of normal healthy skin.
Under normal circumstances, cAMP production is dependant on hormonal activation of receptor sites to stimulate adenylate cyclase. Forskolin bypasses the need for hormonal activation via transmembrane activation.
Tylophora asthmatica is a perennial climber of the ascelpiadiaceae family that is found in the southern and eastern plains of India. It has been used in traditional medicine as an emetic, expectorant, antidysenteric, antirhuematic and bronchial asthma. It's use as an emetic gave it the reputation as the Indian Ipecaccuanha. It was included as an official drug in the Bengal Pharmacoepia of 1884.
In the 1890's, the presence of alkaloids was determined. The isolation of the two main alkaloids, tylophorine and tylophorinine was reported in the 1935. In 1993, tylogenin was isolated from Tylophora sylvatica. Tylogenin is a steroidal compound with antiallergic properties.
The early animal studies showed an anti-psoriasis, seborrheic, anaphylactic effect, leucopenia, and an inhibition of the Schultz-Dale reaction (Haranath, P.S.R.K. and Shyamalakumad, S., Indian J. Med. Res. 63 (1975) 661. Further research showed a smooth muscle relaxant effect, antagonism of smooth muscle stimulants and an inhibition of immunocyto adherence, adjuvant-induced arthritis and release of histamine from mast cells in a variety of animal species.
Two modes of action have been proposed for the dermatological effect of the alkaloids from Tylophora asthmatica. One is that the release of chemical mediators from mast cells is prevented. The alkaloids act as mast cell stabilizers. The other mode of action is through the stimulation of the adrenal gland to maintain high levels of corticosteroids in circulation. Tylophora asthrnatica in the Derma Clear Formulation acts as a mast cell stabilizer. When chemical mediators from mast cells aren't released, there are no triggers to the dermal cells to produce dermatological symptoms.
Ingredients: Coleus forskholii, Tylophora Asthmatica Exrtract, Methylsulfonymethane (MSM), Methyl Paraben, Propyl Paraben, Distilled Water, Alcohol, Glycerine (vegetable), Zinc Citrate( 32.1%)
Suggested Use: Apply to affected areas twice daily or as directed by a health care professional. One dose should cover an area of approximately 9 square inches. Shake well before using. For external use only.